Cara Therapeutics Priced, Nasdaq: CARA
Phase 3-stage biotech developing a novel opioid pain medication.
Industry: Health Care
First Day Return: +17.4%
CARA
Phase 3-stage biotech developing a novel opioid pain medication.
| IPO Data | |
|---|---|
| IPO Date | 01/30/2014 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $55 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Shelton, CT, United States |
| Founded | 2004 |
| Employees at IPO | 11 |
| Website www.caratherapeutics.com | |
IPO News for Cara Therapeutics
Cara Therapeutics (CARA) Performance
